title: [A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
abstract: We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy. A 73-year-old man was diagnosed as having multiple intrahepatic recurrence in segment 2 (S2) and segment 7 (S7) of the liver on abdominal computed tomography (CT) scans 4 years after he underwent liver resection. He was treated with 5 cycles of TACE. Two years and 6 months after the initial TACE, we found that the patient had become refractory to TACE, and therefore, we initiated sorafenib therapy. The response to treatment was stable disease (SD) for 9 months, but the patient's tumor marker levels increased and the tumor gradually increased. Therefore, he underwent additional TACE for the intrahepatic lesions. The patient is still alive with recurrences 4 years and 8 months after the initial recurrence.
authors.affiliation: Dept. of Gastroenterological Surgery, Graduate School of Medicine, Osaka University.
authors.forename: Ryota
authors.initials: R
authors.lastname: Mukai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Wada
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Tomimaru
authors.forename: Naoki
authors.initials: N
authors.lastname: Hama
authors.forename: Koichi
authors.initials: K
authors.lastname: Kawamoto
authors.forename: Shogo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Eguchi
authors.forename: Koji
authors.initials: K
authors.lastname: Umeshita
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D012008:Recurrence; D000077157:Sorafenib; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib